New Merck Research VP Greene Has Advisory Committee Experience
Executive Summary
Douglas Greene, MD, joins Merck Research Laboratories as executive VP-clinical sciences & product development with prior experience serving on FDA's Endocrinologic & Metabolic Drugs Advisory Committee.
You may also be interested in...
Mevacor, Pravachol Rx-To-OTC Switches To Be Considered In July
Rx-to-OTC switch applications for the cholesterol-lowering drugs Mevacor and Pravachol will be reviewed during joint meetings of the Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees July 13 and 14.
Mevacor, Pravachol Rx-To-OTC Switches To Be Considered In July
Rx-to-OTC switch applications for the cholesterol-lowering drugs Mevacor and Pravachol will be reviewed during joint meetings of the Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees July 13 and 14.
Merck Zocor U.S. Sales Headed Past $3 Bil.: Company Sees 20% Growth
U.S. sales of Zocor appear on track to top $3 bil. in 2000 based on projections of 20% growth for the full year.